Wavelength-Pharmaceuticals-Insert
X

Find Novel Oncology Drugs in Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IDE196,Binimetinib

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ideaya Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 18, 2020

            Details:

            IDEAYA and Pfizer will form a Joint Development Committee (JDC), and there will be joint decision making and data sharing of the clinical trial results between the parties.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DNA plasmids

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Ziopharm Oncology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 26, 2020

            Details:

            Ziopharm, based on their analyses of patient tumors, will identify TCRs on a patient-by-patient basis as well as assemble TCRs in a library for use in clinical trials. The company will use Aldevron’s neoGMP service to manufacture multiple DNA plasmids in an expedient.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LNS8801,Pembrolizumab

            Therapeutic Area: Oncology Product Name: LNS8801

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Linnaeus Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 23, 2020

            Details:

            Collaboration agreement aims to study the combination of Linnaeus's lead investigational drug candidate LNS8801, and Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with selected advanced solid tumors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Masked antibody drug conjugate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Adagene (Suzhou) Limited

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 10, 2020

            Details:

            Under the terms of this collaboration, TRL will use Adagene’s SAFEbody™ technology platform to generate a masked antibody in combination with the cytotoxic payload technologies used at TRL, for the development of an ADC against a solid tumor target.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sacituzumab Govitecan

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Janchor Partners

            Deal Size: $310.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing June 05, 2020

            Details:

            Proceeds from the financing will be used to advance clinical development of Everest Medicines’ robust pipeline of novel therapeutic candidates and build out a strong commercial infrastructure to support the next phase of growth.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ONCOS viruses,Microbially derived peptides

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Targovax

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 04, 2020

            Details:

            Leidos and Targovax will investigate the technical feasibility, in vitro and in vivo immune modulatory, and anti-cancer properties of encoding Microtide™ checkpoint peptides in the ONCOS adenovirus backbone.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Irinotecan

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Aposense

            Deal Size: $127.5 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement June 01, 2020

            Details:

            Under this Condition Precedent License Agreement, Aposense will grant Processa a worldwide, royalty-bearing right and license, including the right to sublicense, their next generation irinotecan cancer drug, ATT-11T, upon satisfaction of the set conditions.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 29, 2020

            Details:

            The study emphasizes the importance of comprehensive genomic profiling in patients with METex14-altered NSCLC to facilitate precision medicine both earlier and throughout a patient’s treatment.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pembrolizumab,BgRT

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: RefleXion Medical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 28, 2020

            Details:

            The aim of the clinical collaboration between RefleXion and Merck is to establish whether treating multiple tumors with BgRT, a novel external beam radiotherapy treatment modality in development, is safe and amplifies KEYTRUDA’s therapeutic effect.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CAR-T cell therapies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Viola Group

            Deal Size: $20.0 million Upfront Cash: Undisclosed

            Deal Type: Financing May 15, 2020

            Details:

            Immunai aims to map out the whole immune system. The funds will make a hiring push and will expand its already robust research and development activities.

            PharmaCompass